C-reactive protein and metabolic syndrome in women with previous gestational diabetes

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 2, 2007, Pages 135-140

  Di Cianni, G ^a   Lencioni, C ^a   Volpe, L ^a   Ghio, A ^a   Cuccuru, I ^a   Pellegrinni, G ^b   Benzi, L ^a   Miccoli, R ^a   Del Prato, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

C reactive protein; Gestational diabetes; Insulin sensitivity; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL OBESITY; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK ASSESSMENT; URIC ACID BLOOD LEVEL;

ABDOMEN; ADULT; C-REACTIVE PROTEIN; DIABETES, GESTATIONAL; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; OBESITY; PARITY; PREGNANCY; REFERENCE VALUES; TRIGLYCERIDES;

EID: 33847188535     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.661     Document Type: Article

References (36)

1. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 2002; 25: 1862-1868.
2. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005; 115: 485-491.
3. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 989-993.
4. Meyers-Seyfer CH, Vohr BR. Lipid levels in former gestational diabetic mothers. Diabetes Care 1996; 19: 1351-1356.
5. Anastasiou E, Lekakis J, Alevizaki M, et al. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998; 21: 2111-2115.
6. Kousta E, Lawrence N, Godsland IF, et al. Insulin resistance and β-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin Endocrinol (Oxf) 2003; 59: 289-297.
7. Lencioni C, Volpe L, Miccoli R, et al. Early impairment of beta-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. Nutr Metab Cardiovasc Dis In press.
8. Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior gestational diabetes mellitus. J Clin Endocrinal Metab 1999; 84: 1854-1857.
9. Davis LC, Gutt M, Llabre MM, et al. History of gestational diabetes, insulin resistance and coronary risk. J Diabetes Complications 1999; 13: 216-223.
10. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seelvy EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes. J Clin Endocrinol Metab 2005; 90(7): 3983-3988.
11. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diabetes Care 1991; 14: 173-194.
12. Bo Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73: 2395-2411.
13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
15. Organizing Committee, Metzger BE. Summary and recommendations of the third international workshop conference on gestational diabetes mellitus. Diabetes 1991; 40(Suppl. 2): 197-201.
16. Carpenter MW, Coustan DR. Criteria for screening test for gestational diabetes. Am J Obstet Gynecol 1982; 144: 763-773.
17. American Diabetes Association. Position statement: gestational diabetes mellitus. Diabetes Care 2000; 23(Suppl. 1): S77-S79.
18. National Cholesterol Education Program. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
19. Alberti KGMM, Zimmer P, Show J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28(7): 412-419.
21. Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005; 15: 250-254.
22. Meigs JB, Wilson PWF, Nathan DM, DAgostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham offspring studies. Diabetes Care 2003; 52: 2160-2167.
23. Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25: 1371-1377.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356-359.
25. Albareda M, Caballero A, Badell G, et al. Metabolic syndrome at follow-up in women with and without gestational diabetes mellitus in index pregnancy. Metabolism 2005; 54(8): 1115-1121.
26. Bo S, Monge L, Macchetta C, et al. Prior gestational hyperglycemia: a long-term predictor of the metabolic syndrome. J Endocrinol Invest 2004; 27: 629-635.
27. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005; 90(7): 4004-4010.
28. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes association and the European association for the study of diabetes. Diabetes Care 2005; 28: 2289-2304.
29. Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract 2005; 68: S43-S47.
30. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-1839.
31. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
32. Yeh ET. High-sensitive C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol 2005; 28: 408-412.
33. Wolf M, Sander L, Hsu K, Vossen-Smimaskis K, Eckel JL, Thadhanani R. First trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 2003; 26: 819-824.
34. Wolf M, Sauk J, Shah A, et al. Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. Diabetes Care 2004; 27: 21-27.
35. Pradhan A, Cook N, Buring J, Manson J, Ridker P. C-reactive protein is independently associated with fasting insulin in non diabetic women. Arterioscler Thromb Vasc Biol 2003; 23: 650-655.
36. Ridker PM, Wilson P, Scott M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.